FDA approval of first medical device for treatment of ADHD
The U.S. Food and Drug Administration permitted marketing of the first medical device to treat attention deficit hyperactivity disorder (ADHD). The prescription-only... Read More
Sanofi’s Praluent got much needed boost with USFDA new indication approval
The Food and Drug Administration (FDA) has approved Praluent (alirocumab; Sanofi and Regeneron), a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor,... Read More
Calixar licensing agreement with Regeneron
Calixar SAS, a biotechnology company specialized in native membrane protein stabilization, has entered into an exclusive licensing agreement with Regeneron Pharmaceuticals, Inc.... Read More
Sandoz licensing agreement with EirGenix to commercialize trastuzumab biosimilar
Posted on02 May 2019
TagsBiosimilar, biosimilar deals, biosimilar of sandoz, drug licensing, EirGenix, sandoz, trastuzumab
Comments0
Sandoz, a Novartis division and a global leader in biosimilars, has entered into an agreement to commercialize a proposed trastuzumab biosimilar. This... Read More
Glenmark to introduce SGLT2 inhibitor Remogliflozin in India by licesning collaboration with BHV Pharma
Glenmark Pharmaceuticals is bringing to India Remogliflozin etabonate, a drug used to treat adults with Type 2 diabetes. Glenmark did the phase... Read More